[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
July 10, 2006

Etanercept or Infliximab: The Patient's Considerations—Reply

Arch Intern Med. 2006;166(13):1418. doi:10.1001/archinte.166.13.1418-b

In reply

We appreciate the comments of Sherrick. We agree that medication decision making is complex and that shared decision making with patients is an essential aspect of good patient care. However, research on medical decision making suggests that the majority of physicians (65% in one study1) do not discuss medication expenses with patients. Furthermore, if financial considerations from the patient perspective alone were the primary factor determining biologic drug prescription decisions, one might expect that the proportion of patients with public insurance who received prescriptions for etanercept would be smaller than the 26% observed in our sample.

First Page Preview View Large
First page PDF preview
First page PDF preview
×